PMID- 36372143
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20221206
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 75
DP  - 2022 Dec
TI  - Both donor specific and non-donor specific HLA antibodies reduced in recipients 
      post simultaneous liver/kidney transplant.
PG  - 101744
LID - S0966-3274(22)00218-0 [pii]
LID - 10.1016/j.trim.2022.101744 [doi]
AB  - It has been suggested that the liver allograft can protect the kidney allograft 
      from antibody mediated rejection in simultaneous liver/kidney transplant (SLK) 
      recipients by reducing preexisting donor specific antibodies (DSA) via adsorption 
      of DSA by the liver allograft. Recently, the SLK allocation system was altered to 
      provide a kidney safety net to those who do not recover native kidney function 
      after liver transplant. However, the kidney transplant under the safety net 
      creates a theoretical challenge for sensitized patients as the liver graft may 
      not be able to adsorb human leukocyte antigen (HLA) antibodies against the kidney 
      under the safety net because the liver and kidney grafts are from different 
      donors and may carry different HLA antigens. This prompts us to examine levels of 
      non-donor specific HLA antibodies in SLK recipients in our hospital. We found 
      that levels of both DSA and non-DSA decreased post SLK transplant. The presence 
      of preexisting DSA was also not associated with kidney graft survival and 
      antibody mediated rejection in SLK recipients. Our results indicate that the 
      liver transplant can reduce non-DSA, which may increase the pool of compatible 
      kidneys offered under the safety net program for sensitized patients.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Zhang, Xiaohai
AU  - Zhang X
AD  - Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 
      United States of America. Electronic address: xiaohai.zhang@cshs.org.
FAU - Wisel, Steven A
AU  - Wisel SA
AD  - Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 
      United States of America.
FAU - Haas, Mark
AU  - Haas M
AD  - Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los 
      Angeles, CA, United States of America.
FAU - Kim, Irene
AU  - Kim I
AD  - Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 
      United States of America.
FAU - Jordan, Stanley
AU  - Jordan S
AD  - Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, 
      United States of America.
LA  - eng
PT  - Journal Article
DEP - 20221111
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
RN  - 0 (HLA Antigens)
RN  - 0 (Antibodies)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Humans
MH  - *Kidney Transplantation
MH  - Graft Rejection
MH  - Tissue Donors
MH  - HLA Antigens
MH  - Graft Survival
MH  - Transplant Recipients
MH  - Antibodies
MH  - Liver
MH  - Isoantibodies
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Antibody
OT  - HLA
OT  - SLK
OT  - Safety net
OT  - Simultaneous liver kidney transplant
EDAT- 2022/11/14 06:00
MHDA- 2022/11/30 06:00
CRDT- 2022/11/13 19:23
PHST- 2022/08/17 00:00 [received]
PHST- 2022/11/07 00:00 [revised]
PHST- 2022/11/07 00:00 [accepted]
PHST- 2022/11/14 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/11/13 19:23 [entrez]
AID - S0966-3274(22)00218-0 [pii]
AID - 10.1016/j.trim.2022.101744 [doi]
PST - ppublish
SO  - Transpl Immunol. 2022 Dec;75:101744. doi: 10.1016/j.trim.2022.101744. Epub 2022 
      Nov 11.